Meeder Asset Management Inc Karuna Therapeutics, Inc. Transaction History

Meeder Asset Management Inc

  • $1.42 Billion
  • Q2 2024

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 25, 2024
BUY
$161.01 - $317.85 $420,719 - $830,542
2,613 New
2,613 $827,000
Q4 2021

Feb 11, 2022
SELL
$110.64 - $159.4 $331 - $478
-3 Closed
0 $0
Q1 2021

Apr 28, 2021
BUY
$95.46 - $133.08 $286 - $399
3 New
3 $0
Q4 2020

Feb 09, 2021
SELL
$75.23 - $109.23 $752 - $1,092
-10 Closed
0 $0
Q3 2020

Nov 02, 2020
SELL
$71.31 - $109.74 $641 - $987
-9 Reduced 47.37%
10 $1,000
Q2 2020

Aug 11, 2020
SELL
$62.14 - $117.21 $4,846 - $9,142
-78 Reduced 80.41%
19 $2,000
Q1 2020

May 15, 2020
BUY
$60.41 - $115.92 $5,859 - $11,244
97 New
97 $7,000

Others Institutions Holding KRTX

# of Institutions
10
Shares Held
332K
Call Options Held
0
Put Options Held
0
View Full List

About Karuna Therapeutics, Inc.

KRTX Quotes by TradingView
  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Meeder Asset Management Inc Portfolio

Follow Meeder Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email